1-20 of 326029
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pretransplant targeting of TNFRSF25 and CD25 stimulates recipient Tregs in target tissues, ameliorating GVHD post-HSCT

Open Access
Duneia McManus, Sabrina N. Copsel, Brent J. Pfeiffer, Dietlinde Wolf, Henry Barreras, Symon Ma, Ali Khodor, Seitaro Komai, Marina Burgos da Silva, Hajar Hazime, Miguel Gallardo, Sarah Grace Lime, Marcel R. M. van den Brink, Jung-Hyun Park, Maria T. Abreu, Geoffrey R. Hill, Victor L. Perez, Robert B. Levy
Journal: Blood
Blood (2025) 146 (22): 2710–2727.
https://doi.org/10.1182/blood.2025028418
Published: 2025
Includes: Supplemental data
Journal Articles

Improved diagnostic screening and classification of clonal mast cell diseases by ultrasensitive KIT p.D816V detection

Available to Purchase
Paula Navarro-Navarro, María González-Tablas, Alba Pérez-Pons, Laura Sánchez-Muñoz, Ana Henriques, Iván Álvarez-Twose, Paula Nafria, David Araco-Sánchez, Cristina Morales-Cabeza, Horacio Caligaris, Lei Chen, David González-de-Olano, Óscar González-López, Luis Escribano, Andrés C. García-Montero, María Jara-Acevedo, Alberto Orfao
Journal: Blood
Blood (2025) 146 (22): 2696–2709.
https://doi.org/10.1182/blood.2025029507
Published: 2025
Includes: Supplemental data
Journal Articles

Proteomic subtypes enrich current acute myeloid leukemia nomenclature and reflect intrinsic pathogenesis alongside aging

Open Access
Wen-Yan Cheng, Xiao Yi, Zhen-Yi Wang, Jian-Feng Li, Jun-Yi Zhang, Rui-Hong Zhang, Qian-Qian Zhang, Xiang-Qin Weng, Ting Huang, Yong-Mei Zhu, Chao Wang, Wei Yin, Jia-Nan Zhang, Hui-Yi Wu, Jun-Min Li, Hong-Ming Zhu, Li Chen, Wen-Fang Wang, Yu-Ting Dai, Chen-Xu Gao, Xuan Liu, Shan Wang, Sheng-Yue Wang, Bo Jiao, Zhu Chen, Hai Fang, Tong Yin, Yang Shen, Sai-Juan Chen
Journal: Blood
Blood (2025) 146 (22): 2681–2695.
https://doi.org/10.1182/blood.2024027692
Published: 2025
Includes: Supplemental data
Journal Articles

Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling

Open Access
Clinical Trials & Observations
Sina A. Beer, David A. Cairns, Charlotte Pawlyn, Amy Holroyd, Elsa Ferris, Gordon Cook, Mark Drayson, Kevin Boyd, Paula Proszek, Faith E. Davies, Ruth de Tute, Matthew Jenner, Gareth J. Morgan, Roger Owen, Michael Hubank, Richard Houlston, Graham Jackson, Martin F. Kaiser
Journal: Blood
Blood (2025) 146 (22): 2670–2680.
https://doi.org/10.1182/blood.2025029987
Published: 2025
Includes: Supplemental data
Journal Articles

A prime editing strategy to rewrite the γ-globin promoters and reactivate fetal hemoglobin for sickle cell disease

Open Access
Brief Report
Anne Chalumeau, Maria Bou Dames, Letizia Fontana, Simone Amistadi, Panagiotis Antoniou, Priyanka Loganathan, Margaux Mombled, Guillaume Corre, Martin Peterka, Mario Amendola, Carine Giovannangeli, Marcello Maresca, Annarita Miccio, Mégane Brusson
Journal: Blood
Blood (2025) 146 (22): 2641–2655.
https://doi.org/10.1182/blood.2024028166
Published: 2025
Includes: Supplemental data
Journal Articles

Innate lymphoid cells prevent graft-versus-host disease via IL-9–driven T-cell senescence

Available to Purchase
Dejene M. Tufa, Eric Hoffmeyer, Kristin L. Schaller, Ben Kooiman, Elena Woods, Dong Wang, Dallas Jones, Spencer Hall, Joselyn Cruz Cruz, Michael R. Verneris
Journal: Blood
Blood (2025) 146 (22): 2656–2669.
https://doi.org/10.1182/blood.2025028504
Published: 2025
Includes: Supplemental data
Journal Articles

Fixed-duration epcoritamab plus R 2 drives favorable outcomes in relapsed or refractory follicular lymphoma

Open Access
Clinical Trials & Observations
Lorenzo Falchi, Anna Sureda, Sirpa Leppä, Joost S. P. Vermaat, Marcel Nijland, Jacob Haaber Christensen, Sven de Vos, Harald Holte, Reid W. Merryman, Pieternella J. Lugtenburg, Pau Abrisqueta, Kim M. Linton, Gauri Sunkersett, Daniela Hoehn, Ali Rana, Aqeel Abbas, Jennifer Marek, Yi Hao, Andrew J. Steele, Christopher Morehouse, Martin Hutchings, David Belada
Journal: Blood
Blood (2025) 146 (22): 2629–2640.
https://doi.org/10.1182/blood.2025029909
Published: 2025
Includes: Supplemental data
Journal Articles

Old but gold: ILC-induced T-cell senescence prevents GVHD

Free
Sophia Chen
Journal: Blood
Blood (2025) 146 (22): 2620–2621.
https://doi.org/10.1182/blood.2025030805
Published: 2025
Journal Articles

MASTering KIT : enhanced sensitivity for refined diagnosis

Free
Yannick Chantran, Michel Arock
Journal: Blood
Blood (2025) 146 (22): 2624–2626.
https://doi.org/10.1182/blood.2025030940
Published: 2025
Journal Articles

Death receptor 3 gives life to Tregs in GVHD

Free
Haroon Shaikh
Journal: Blood
Blood (2025) 146 (22): 2626–2627.
https://doi.org/10.1182/blood.2025030671
Published: 2025
Journal Articles

Better together: epcoritamab boosts R2 in FL

Free
Clinical Trials & Observations
Umberto Vitolo, Francesca Bonello
Journal: Blood
Blood (2025) 146 (22): 2617–2619.
https://doi.org/10.1182/blood.2025031236
Published: 2025
Journal Articles

Above the cut: HbF induction by multiplex prime editing

Free
Carsten W. Lederer
Journal: Blood
Blood (2025) 146 (22): 2619–2620.
https://doi.org/10.1182/blood.2025031005
Published: 2025
Journal Articles

Explain the unexplained

Free
Jill Corre
Journal: Blood
Blood (2025) 146 (22): 2622–2623.
https://doi.org/10.1182/blood.2025030944
Published: 2025
Journal Articles

Proteomics: the key to understanding AML hematopoietic aging

Free
Sara J. C. Gosline
Journal: Blood
Blood (2025) 146 (22): 2623–2624.
https://doi.org/10.1182/blood.2025030883
Published: 2025
Journal Articles

Yeung DT, Shanmuganathan N, Reynolds J, et al; Australasian Leukaemia and Lymphoma Group. Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study. Blood. 2024;144(19):1993-2001.

Free
Journal: Blood
Blood (2025) 146 (22): 2729.
https://doi.org/10.1182/blood.2025031951
Published: 2025
Journal Articles

FLI1 -related thrombocytopenia: piecing together the story

Free
Richard C. Godby, Dong Chen
Journal: Blood
Blood (2025) 146 (22): 2728.
https://doi.org/10.1182/blood.2025030799
Published: 2025
Images
Transformative impact of Flow-SuperRCA on the diagnostic landscape of clonal MCDs. This figure illustrates the transformative impact of Flow-SuperRCA technology compared with the conventional ASO-qPCR method for detecting KIT p.D816V in MCAS and SM including BMM. The left panel summarizes the current limitations of ASO-qPCR, including its restricted sensitivity (LOD: 0.01%), the frequent need for BM biopsy, and the potential for diagnostic uncertainty or misclassification, particularly in patients with low mast cell burden, such as MMAS, BMM, and nc-MCAS. The middle panel emphasizes the key advantages of Flow-SuperRCA, which offers a 10-fold increase in sensitivity (LOD: 0.001%) and enables direct detection of KIT p.D816V in PB and BM samples. This enhanced performance results in reclassification of 18% of previously diagnosed nc-MCAS cases as clonal MCAS, and in detection of BMM cases without skin involvement, cases often missed by ASO-qPCR. The right panel outlines the downstream clinical implications of implementing Flow-SuperRCA, including earlier diagnosis, reduced need for invasive procedures (PB-based screening), improved identification of clonal MCD, and potential for MRD monitoring. In clinical terms, Flow-SuperRCA increased detection rates in MMAS (64% vs 7% with ASO-qPCR), and achieved a diagnostic accuracy of 88% in PB across all SM subtypes, substantially higher than ASO-qPCR (57%). These results support its integration into updated diagnostic algorithms and WHO/ECNM classifications. ECNM, European Competence Network on Mastocytosis; LOD, limit of detection; MRD, minimal residual disease; WHO, World Health Organization.

Transformative impact of Flow-SuperRCA on the diagnostic landscape of clona...

Free
in MASTering KIT : enhanced sensitivity for refined diagnosis > Blood
Published: 2025
Transformative impact of Flow-SuperRCA on the diagnostic landscape of clonal MCDs. This figure illustrates the transformative impact of Flow-SuperRCA technology compared with the conventional ASO-qPCR method for detecting KIT p.D816V in MCAS and SM including BMM. The left panel summarizes the curr... More about this image found in Transformative impact of Flow-SuperRCA on the diagnostic landscape of clona...
Images
TL1A-Ig and IL-2LD treatment expands tissue-resident Tregs and restrains alloreactive T-cell–driven damage in GVHD target organs. Professional illustration by Patrick Lane, ScEYEnce Studios.

TL1A-Ig and IL-2 LD treatment expands tissue-resident Tregs and restrains ...

Free
in Death receptor 3 gives life to Tregs in GVHD > Blood
Published: 2025
TL1A-Ig and IL-2 LD treatment expands tissue-resident Tregs and restrains alloreactive T-cell–driven damage in GVHD target organs. Professional illustration by Patrick Lane, ScEYEnce Studios. More about this image found in TL1A-Ig and IL-2 LD treatment expands tissue-resident Tregs and restrains ...
Images
Study overview and risk profiles of ER patients. (A) Functional HR MM in 135 MyXI trial patients was determined using advanced molecular profiling, including HRCA per updated IMS/IMWG-HR criteria and GEP-HR based on the SKY92 signature. (B) Bar chart illustrating the composition of 4 risk groups based on IMS/IMWG-HR and GEP-HR classification (SR, IMS/IMWG-HR, GEP-HR, and IMS/IMWG-HR & GEP-HR) in the 25 patients with ER. CTPC, circulating tumor plasma cells; Lena, lenalidomide; PCL, plasma cell leukemia. Figure created with biorender.com. Houlston R. (2025) https://biorender.com/0vv82j9.

Study overview and risk profiles of ER patients. (A) Functional HR MM in 1...

Open Access
in Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling > Blood
Published: 2025
Figure 1. Study overview and risk profiles of ER patients. (A) Functional HR MM in 135 MyXI trial patients was determined using advanced molecular profiling, including HRCA per updated IMS/IMWG-HR criteria and GEP-HR based on the SKY92 signature. (B) Bar chart illustrating the composition of 4 r... More about this image found in Study overview and risk profiles of ER patients. (A) Functional HR MM in 1...
Images
Kaplan-Meier survival estimates for the entire study cohort (n = 135). (A) PFS and (B) OS stratified by IMS/IMWG-HR and GEP-HR classification (SR, IMS/IMWG-HR, GEP-HR, IMS/IMWG-HR & GEP-HR). x-axis, time since maintenance randomization (months); y-axis, survival probability; risk tables, number of patients at risk. Log-rank P values are shown. Figure created with biorender.com. Houlston R. (2025) https://biorender.com/0vv82j9.

Kaplan-Meier survival estimates for the entire study cohort (n = 135). (A)...

Open Access
in Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling > Blood
Published: 2025
Figure 2. Kaplan-Meier survival estimates for the entire study cohort (n = 135). (A) PFS and (B) OS stratified by IMS/IMWG-HR and GEP-HR classification (SR, IMS/IMWG-HR, GEP-HR, IMS/IMWG-HR & GEP-HR). x-axis, time since maintenance randomization (months); y-axis, survival probability; risk t... More about this image found in Kaplan-Meier survival estimates for the entire study cohort (n = 135). (A)...